REFERENCES
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70:200-29.
3. Gonzalez MR, Bryce-Alberti M, Leon-Abarca JA, Pretell-Mazzini J. Brain metastases in patients with soft-tissue sarcomas: management and survival-a SEER population-based cohort study. J Am Acad Orthop Surg Glob Res Rev. 2021;5:1-10.
4. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20.
5. Von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:536-63.
6. Kawae Y, Matsuoka M, Onodera T, et al. Liver metastasis in soft tissue sarcoma at initial presentation. J Surg Oncol. 2022;126:1074-9.
7. Younis MH, Summers S, Pretell-Mazzini J. Bone metastasis in extremity soft tissue sarcomas: risk factors and survival analysis using the SEER registry. Musculoskelet Surg. 2022;106:59-68.
8. Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15:109.
9. Shah NK, Yegya-Raman N, Jones JA, Shabason JE. Radiation therapy in metastatic soft tissue sarcoma: from palliation to ablation. Cancers. 2021;13:4775.
10. Casali PG, Abecassis N, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv51-67.
11. Haddox CL, Riedel RF. Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology. Expert Rev Anticancer Ther. 2020;20:5-8.
12. Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2003;8:541-52.
13. Gonzalez MR, Bryce-Alberti M, Portmann-Baracco A, Inchaustegui ML, Castillo-Flores S, Pretell-Mazzini J. Appendicular dedifferentiated chondrosarcoma: a management and survival study from the SEER database. J Bone Oncol. 2022;37:100456.
14. Gonzalez MR, Bryce-Alberti M, Portmann-Baracco A, Castillo-Flores S, Pretell-Mazzini J. Treatment and survival outcomes in metastatic Merkel cell carcinoma: analysis of 2010 patients from the SEER database. Cancer Treat Res Commun. 2022;33:100665.
15. Ferguson PC, Deheshi BM, Chung P, et al. Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. Cancer. 2011;117:372-9.
16. Krishnan CK, Kim HS, Park JW, Han I. Outcome after surgery for extremity soft tissue sarcoma in patients presenting with metastasis at diagnosis. Am J Clin Oncol. 2018;41:681-6.
17. Tao X, Hou Z, Wu Z, Hao S, Liu B. Brain metastatic alveolar soft-part sarcoma: clinicopathological profiles, management and outcomes. Oncol Lett. 2017;14:5779-84.
18. Knebel C, Lenze U, Pohlig F, et al. Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years. BMC Cancer. 2017;17:410.
20. Van Gaal JC, Van Der Graaf WTA, Rikhof B, et al. The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. Anticancer Res. 2012;32:4485-98.
21. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children’s oncology group. Pediatr Blood Cancer. 2004;42:64-73.
22. Akinyemiju T, Sakhuja S, Waterbor J, Pisu M, Altekruse SF. Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer. Cancer Med. 2018;7:1183-93.
23. Akinyemiju TF, Vin-Raviv N, Chavez-Yenter D, Zhao X, Budhwani H. Race/ethnicity and socio-economic differences in breast cancer surgery outcomes. Cancer Epidemiol. 2015;39:745-51.
24. Lewis SJ, Wunder JS, Couture J, et al. Soft tissue sarcomas involving the pelvis. J Surg Oncol. 2001;77:8-14; discussion 15.
25. Keyzer-Dekker CM, Houtkamp RG, Peterse JL, Van Coevorden F. Adult pelvic sarcomas: a heterogeneous collection of sarcomas? Sarcoma. 2004;8:19-24.
26. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260:416-21; discussion 421-2.
27. Smith HG, Memos N, Thomas JM, Smith MJ, Strauss DC, Hayes AJ. Patterns of disease relapse in primary extremity soft-tissue sarcoma. Br J Surg. 2016;103:1487-96.
28. Jain S, Xu R, Prieto VG, Lee P. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol. 2010;3:416-28.
29. Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg. 1995;221:392-7.
30. Smolle MA, Leithner A, Bernhardt GA. Abdominal metastases of primary extremity soft tissue sarcoma: a systematic review. World J Clin Oncol. 2020;11:74-82.
31. Grimme FAB, Seesing MFJ, van Hillegersberg R, et al. Liver resection for hepatic metastases from soft tissue sarcoma: a nationwide study. Dig Surg. 2019;36:479-86.
32. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384-9.
33. Smith HG, Thomas JM, Smith MJF, Hayes AJ, Strauss DC. Major amputations for extremity soft-tissue sarcoma. Ann Surg Oncol. 2018;25:387-93.
34. Lindsay AD, Haupt EE, Chan CM, et al. Treatment of sarcoma lung metastases with stereotactic body radiotherapy. Sarcoma. 2018;2018:9132359.
35. Loi M, Duijm M, Baker S, et al. Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma. Radiol Med. 2018;123:871-8.
